Rambeck B, May T W, Jürgens M U, Blankenhorn V, Jürges U, Korn-Merker E, Sälke-Kellermann A
Department of Biochemistry, Gesellschaft für Epilepsieforschung e. V., Bethel, Germany.
Ther Drug Monit. 1994 Dec;16(6):608-12. doi: 10.1097/00007691-199412000-00013.
Steady-state concentrations of phenytoin (PHT) and carbamazepine (CBZ) were measured by a novel patient-side immunoassay system with a single-use cartridge (Biotrack 516). The Biotrack determinations were performed in whole blood and extrapolated to serum on the basis of the hemoglobin content. The results were compared with serum concentrations measured by high-performance liquid chromatography (HPLC) or the standard TDx and enzyme multiplied immunoassay (EMIT) techniques. A total of 222 samples from epileptic patients on PHT and 322 samples from patients on CBZ were analyzed. In the case of PHT there was a highly linear correlation [r = 0.985, y = 1.113x-0.589; x = HPLC, y = Biotrack] between HPLC and the Biotrack system in the concentration range of 2.5-30 micrograms/ml. In the case of CBZ, the correlation between HPLC and the Biotrack system in the concentration range of 2.0-20 micrograms/ml was somewhat lower [r = 0.931, y = 1.29x-0.136; x = HPLC, y = Biotrack]. Comparable results were also found for the correlation of the Biotrack system with the TDx assay or with the EMIT assay, respectively. Comedication had no influence, or only a minor influence (valproic acid), on the concentration of PHT and CBZ measured by the Biotrack system. Furthermore, the concentration of the metabolite carbamazepine-10, 11-epoxide had no influence on the concentration of CBZ measured by the Biotrack system. Since the automated cartridge system is simple, can be used rapidly, and is performed with only a few drops of blood, this technique offers some advantages for routine clinical use, especially under outpatient conditions.
采用一种带有一次性试剂盒的新型患者端免疫分析系统(Biotrack 516)测定苯妥英(PHT)和卡卡马西平(CBZ)的稳态浓度。Biotrack测定在全血中进行,并根据血红蛋白含量外推至血清浓度。将结果与通过高效液相色谱法(HPLC)或标准TDx和酶放大免疫分析(EMIT)技术测定的血清浓度进行比较。共分析了222份来自服用PHT的癫痫患者的样本和322份来自服用CBZ的患者的样本。对于PHT,在2.5 - 30微克/毫升的浓度范围内,HPLC与Biotrack系统之间存在高度线性相关性[r = 0.985,y = 1.113x - 0.589;x = HPLC,y = Biotrack]。对于CBZ,在2.0 - 20微克/毫升的浓度范围内,HPLC与Biotrack系统之间的相关性稍低[r = 0.931,y = 1.29x - 0.136;x = HPLC,y = Biotrack]。Biotrack系统与TDx测定或EMIT测定的相关性也得到了类似结果。合并用药对Biotrack系统测定的PHT和CBZ浓度没有影响,或仅有轻微影响(丙戊酸)。此外,代谢产物卡马西平 - 10,11 - 环氧化物的浓度对Biotrack系统测定的CBZ浓度没有影响。由于这种自动化试剂盒系统操作简单、使用快速,且仅需几滴血液即可进行检测,因此该技术在常规临床应用中具有一些优势,尤其是在门诊条件下。